Investors Want to Develop Biontech into A Pharmaceutical Company

Main investor Thomas Strungmann wants to turn the vaccine developer into an “independent, fully integrated pharmaceutical company from Germany”. He rules out a sale in the long term. After the…

Read More

Page 1 of 1